Pluri Inc.

PLUR

NASDAQHealthcareBiotechnology

在 GoAI 中打開

GoAI 研究快照

簡明呈現最新可用的模型資訊。

2026年7月10日

32/ 100

GoAI評分

Sell

Trim exposure — unfavorable risk-reward

估值

Expensive

動能

Weakening

情緒

Mixed

風險韌性

High Risk

完整 GoAI 研究

繼續查看更深入的依據、催化因素和風險。

看完整研究

人工智慧產生的上下文僅供參考，並非投資建議。

公司概況

公司網站

Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.

產業: Biotechnology
部門: Healthcare
總部: IL
執行長: Yaacov Yanay
上市以來: 2003年6月30日
僱員: 127